PatientsVille.com Logo


Anemia Medical Research Studies

Up-to-date List of Anemia Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Anemia Medical Research Studies

Rank Status Study
1 Recruiting Microvascular Blood Flow in Sickle Cell Anemia
Conditions: Sickle Cell Disease;   Sickle Cell Anemia
Interventions: Drug: regadenoson infusion with contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound
Outcome Measures: Microvascular Blood Flow in Sickle Cell Anemia with Regadenoson Use;   Microvascular Blood Flow in Sickle Cell Anemia with Hydroxyurea Use;   Changes in Microvascular Blood Flow in Subjects with Sickle Cell Anemia During a Pain Crisis;   Microvascular Blood Flow in Sickle Cell Anemia Subjects Versus Control Subjects
2 Recruiting Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
Outcome Measures: Identification of children at high risk of having Fanconi Anemia;   Identification of Fanconi Anemia patients
3 Recruiting Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Very Severe Aplastic Anemia;   Moderate Aplastic Anemia
Intervention: Drug: Eltrombopag
Outcome Measures: Platelet Count Response;   Platelet count twice baseline.;   Hematology labs;   Number of patients with AE to measure toxicity, using NCI CTCAE;   Characterization of the PK profile of eltrombopag in patients with moderate to very severe aplastic Anemia. Evaluated with AUC, Cmax, Cmin, tmax.
4 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
Outcome Measure: Rate of engraftment
5 Recruiting Therapeutic Use of the Amino Acid, Leucine in the Treatment of Transfusion - Dependent Diamond Blackfan Anemia Patients
Conditions: Diamond Blackfan Anemia;   Blackfan Diamond Syndrome;   DBA;   Congenital Hypoplastic Anemia;   Pure Red Cell Aplasia
Intervention: Drug: leucine
Outcome Measures: Response to Leucine in Transfusion dependent patients with Diamond Blackfan Anemia;   Side effects of leucine in transfusion-dependent DBA patients
6 Recruiting Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.
Conditions: Anemia;   Iron Deficiency
Intervention: Drug: Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
Outcome Measures: Red blood cell (RBC) units transfused;   Percentage of patients without any RBC transfusions;   Combined allogeneic transfusions (RBC, FFP( fresh frozen plasma), platelets);   Length of stay in the intensive care unit (ICU);   Duration of mechanical ventilation;   Acute kidney failure;   Major Adverse Cardiac and Cerebrovascular Events (MACCE);   New atrial fibrillation;   Infections;   Thrombotic and thromboembolic complications (90 days);   Length of stay (LOS) in the hospital;   Length of hospital stay (in comparison to median LOS published for relevant Swiss-DRGs);   In hospital mortality;   30 day and 90-day mortality;   Costs (for blood products and pharmaceutical products related to transfusion and Anemia management);   Perioperative Hb concentrations;   Calculated RBC and blood loss;   Comparison of the treatment and placebo groups with the natural comparison group;   Safety and tolerance of administered study drug and placebo
7 Recruiting Mechanisms Accounting for Unexplained Anemia in the Elderly
Conditions: Normal Aging;   Anemia
Intervention: Procedure: Biotin RBC survival
Outcome Measures: Red blood cell survival in Anemia and control subjects.;   Inflammatory marker, red cell metabolic alternating, white blood cell mitochondrial DNA changes in Anemia patients.
8 Recruiting Eltrombopag for Moderate Aplastic Anemia
Conditions: Eltrombopag;   Aplastic Anemia;   Aplastic Anemia Treatment;   Moderate Aplastic Anemia;   Moderate Aplastic Anemia Treatment
Intervention: Drug: Eltrombopag
Outcome Measures: The portion of drug responders as defined by changes in the platelet count and/or platelet transfusion requirements or hemoglobin and/or PRBC transfusion requirements and the toxicity profile as measured using the CTCAE criteria.;   Incidence of bleeding, changes in serum thrombopoietin level, and health related quality of life (as measured by the Medical Outcomes Study 36-Item Short Form General Health Survey, version 2 [SF36v2] Quality-Metric) measured at 16 weeks.
9 Not yet recruiting The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.
Condition: Iron-Deficiency Anemias,
Outcome Measure: thrombin generation levels
10 Not yet recruiting Treatment of Iron Deficiency Anemia With Pregnancy
Condition: Iron Deficiency Anemia of Pregnancy
Interventions: Drug: amino acid chelated iron;   Drug: iron salt (ferrous fumarate)
Outcome Measures: change in hemoglobin level;   the occurence of side effects (abdominal colics, constipation, or metallic taste);   change in serum ferritin level
11 Recruiting Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
Condition: Fanconi Anemia
Interventions: Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
Outcome Measures: Percent of Graft Failure;   Incidence of Acute and Chronic Graft-Versus-Host Disease;   Incidence of Relapse;   Incidence of Major Infections;   Transplant-Related Toxicity;   Overall Survival;   Incidence of Chronic Graft-Versus-Host Disease
12 Recruiting Longitudinal Changes in Exercise Capacity in Children and Young Adults With Sickle Cell Anemia
Condition: Sickle Cell Anemia
Outcome Measures: VO2 max on cardiopulmonary exercise test;   Quality of life questionnaires;   Echocardiogram;   Dual Energy X-ray Absorbtiometry;   Pulmonary Function Test
13 Unknown  A Functional Food for the Prevention of Iron-deficiency Anemia
Condition: Anemia
Interventions: Other: Control bread;   Other: Teff Bread
Outcome Measures: To develop Teff bread that is rich in iron (per slice).;   To establish whether iron from Teff is bioavailable.;   To conclude whether daily Teff consumption prevents iron-deficiency Anemia in pregnancy.;   To use a range of different biomarkers to determine iron status.;   To compare dietary intakes of iron and iron status between the Teff/control group.
14 Recruiting Quercetin in Children With Fanconi Anemia; a Pilot Study
Condition: Fanconi Anemia
Intervention: Drug: Quercetin (dietary supplement)
Outcome Measures: Measure the ability to administer twice daily oral quercetin therapy in patients with Fanconi Anemia (FA).;   Measure safety of oral quercetin therapy in patients with FA;   To measure pharmacokinetics (PK) of oral quercetin therapy in patients with FA;   To measure the impact of quercetin therapy on reduction of Reactive Oxygen Species (ROS).;   Number of participants with improved hematopoiesis.;   Measure the preservation of hematopoietic stem cell reserve in patients with FA;   Number of participants with changes in insulin sensitivity/glucose tolerance.
15 Recruiting A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis
Condition: Anemia
Interventions: Drug: FG-4592;   Drug: Placebo
Outcome Measures: Efficacy of FG-4592 - Anemia correction;   Efficacy of FG-4592 - Maintenance of hemoglobin levels;   Evaluate the need for Anemia rescue therapy, such as blood transfusion, intravenous Iron, or injectable erythrocyte stimulating therapies;   Safety of FG-4592;   FG-4592 Tolerability
16 Recruiting Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects With Chronic Kidney Disease
Conditions: Anemia;   Chronic Kidney Disease;   Kidney Disease
Interventions: Drug: darbepoetin alfa QW;   Drug: darbepoetin alfa Q2W
Outcome Measures: To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa QW for treatment of Anemia in pediatric CKD subjects receiving;   To test if the proportion of subjects achieving a Hb value >/= 10.0 g/dL at any time point after the first dose during the study is greater than 0.8 when administered de novo darbepoetin alfa Q2W for treatment of Anemia in pediatric CKD subjects receivin;   To assess the health-related quality of life in pediatric CKD subjects >/= 2 years old over the duration of the study in the QW and Q2W arms;   To obtain pharmacokinetic (PK) data in subjects < 6 years of age;   To assess the safety and tolerability of darbepoetin alfa administered QW and Q2W;   To estimate Hb values over the duration of the study in the QW and Q2W arms;   To estimate doses over the duration of the study in the QW and Q2W arms
17 Recruiting The Benefits of a Preoperative Anemia Management Program
Condition: Anemia, Iron-Deficiency
Interventions: Drug: Iron sucrose;   Drug: Epoetin Alfa;   Other: Blood Transfusion
Outcome Measures: Need for blood transfusion during and after surgery.;   Health-related quality of life
18 Recruiting Alemtuzumab to Treat Severe Aplastic Anemia
Conditions: Relapsed or Refractory Severe Aplastic Anemia;   Severe Aplastic Anemia
Intervention: Drug: Alemtuzumab (Campath )
Outcome Measures: Response rate at six months, defined as no longer satisfying blood count criteria for SAA.;   Relapse, robustness of the hematopoietic recovery at three and six months, three months responses, survival, and clonal evolution to myelodysplasia and acute leukemia.
19 Unknown  Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)
Condition: Aplastic Anemia
Intervention: Other: Cyclophosphosphamide, TBI
Outcome Measures: To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for cord blood transplantation (CBT) in severe aplastic Anemia.;   To evaluate the incidence and severity of toxicity and treatment related mortality;   To evaluate overall and event free survival rate;   To evaluate acute and chronic GVHD;   To evaluate immunologic recovery after CBT
20 Unknown  Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
Conditions: Anemia;   Leukemia;   Leukemia, Myelocytic, Acute;   Dysmyelopoietic Syndromes
Intervention: Drug: Lenalidomide
Outcome Measures: RBC transfusion independence;   >50% decrease in RBC transfusion requirements;   Change of hemoglobin concentration from baseline;   Neutrophil response;   Platelet response;   Bone marrow response;   Duration of response;   Safety (type, frequency, severity, and relationship of adverse events to lenalidomide);   Correction of clinical response with ribosomal protein mutation status and ex vivo effects of lenalidomide on marrow erythroid colony growth and microarray gene expression signatures

These studies may lead to new treatments and are adding insight into Anemia etiology and treatment.

A major focus of Anemia research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Anemia